Breaking News Instant updates and real-time market news.

MRK

Merck

$61.19

-1 (-1.61%)

07:05
12/01/16
12/01
07:05
12/01/16
07:05

Merck says FDA grants priority review to sBLA for Keytruda in relapsed cHL

Merck announced that the U.S. FDA has accepted for review the supplemental Biologics License Application for KEYTRUDA, the company's anti-PD-1 therapy, for the treatment of patients with refractory classical Hodgkin lymphoma or for patients who have relapsed after three or more prior lines of therapy. The FDA granted Priority Review with a PDUFA, or target action, date of March 15, 2017. The sBLA will be reviewed under the FDA's Accelerated Approval program. In April 2016, KEYTRUDA was granted Breakthrough Therapy Designation by the FDA for this indication. The application is seeking approval for KEYTRUDA at a fixed dose of 200 mg administered intravenously every three weeks and is based on data from the KEYNOTE-087 and KEYNOTE-013 trials, which studied patients with refractory cHL or who had relapsed after three or more prior lines of therapy. This is the first application for regulatory approval of KEYTRUDA in a hematologic malignancy. The KEYTRUDA clinical development program includes more than 30 tumor types in more than 360 clinical trials, including nearly 200 trials that combine KEYTRUDA with other cancer treatments. For hematologic malignancies specifically, Merck is conducting broad immuno-oncology research assessing the role of monotherapy and combination regimens with KEYTRUDA. The program includes nearly 40 ongoing studies - several of which are registration-enabling trials - across more than 20 hematologic subtypes, including leukemia, lymphomas and myeloma.

  • 01

    Dec

  • 03

    Dec

  • 08

    Mar

MRK Merck
$61.19

-1 (-1.61%)

10/13/16
10/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Buy from Neutral at BofA/Merrill with analyst Colin Bristow citing its opportunity in first line lung cancer. 2. Viacom (VIA, VIAB) upgraded to Market Perform from Underperform at Wells Fargo and to Buy from Underperform at BofA/Merrill. 3. TD Ameritrade (AMTD) and Charles Schwab (SCHW) were upgraded to Buy from Neutral at BofA/Merrill. 4. Talend (TLND) upgraded to Buy from Neutral at Goldman with analyst Jesse Hulsing saying the company will benefit from analytic workloads moving to the cloud. 5. CSC (CSC) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/19/16
LEER
10/19/16
NO CHANGE
LEER
Roche Tecentriq approval increases competition, says Leerink
Leerink analyst Seamus Fernandez says that the FDA approval of Roche's (RHHBY) Tecentriq in second-line non-small cell lung cancer patients regardless of PD-L1 expression comes as no surprise given its previously reported overall survival advantage. Nonetheless, the analyst believes it creates new competition for Bristol-Myers' (BMY) Opdivo and Merck's (MRK) Keytruda in this setting.
10/24/16
RHCO
10/24/16
NO CHANGE
RHCO
Merck Keytruda to have several positive catalysts, says SunTrust
SunTrust analyst John Boris says that several trials of Merck's Keytruda will be stopped early "across multiple tumor types," providing a positive catalyst. Boris says that Keytruda should be approved for 1LNSCLC on or before December 24 and KN-21 chemo combo compendium listing in 1H17. He keeps a $73 price target and Buy rating on Merck.
10/25/16
RHCO
10/25/16
NO CHANGE
RHCO
Merck shares should be bought after early FDA approval, says SunTrust
After Merck announced that the FDA had approved the company's Keytruda treatment for the first-line metastatic non-small cell lung cancer with tumor proportion scores of 50% or higher, SunTrust analyst John Boris says that such patients represent about 30% "of the prevalent first-line population." He adds that the approval was earlier than expected and gives Keytruda an approximately 15 month lead over competing drugs in NSCLC. The analyst thinks that the early approval will enable the company's 2021 revenue to beat expectations by a significant amount, and he recommends buying the stock on the news.

TODAY'S FREE FLY STORIES

ICPT

Intercept

$73.70

-24.42 (-24.89%)

09:31
09/22/17
09/22
09:31
09/22/17
09:31
Downgrade
Intercept rating change  »

Citi downgrades Intercept…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MHK

Mohawk

09:31
09/22/17
09/22
09:31
09/22/17
09:31
Downgrade
Mohawk rating change  »

Mohawk downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UFCS

United Fire Group

$42.02

-0.12 (-0.28%)

09:30
09/22/17
09/22
09:30
09/22/17
09:30
Upgrade
United Fire Group rating change  »

United Fire Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:30
09/22/17
09/22
09:30
09/22/17
09:30
General news
PMI Composite Flash Manufacturing â€' Level to be reported at 09:45 »

September PMI Composite…

09:30
09/22/17
09/22
09:30
09/22/17
09:30
General news
PMI Composite Flash â€' Level to be reported at 09:45 »

September PMI Composite…

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

09:28
09/22/17
09/22
09:28
09/22/17
09:28
Recommendations
YogaWorks analyst commentary  »

YogaWorks shares remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IP

International Paper

09:28
09/22/17
09/22
09:28
09/22/17
09:28
Hot Stocks
International Paper to invest about $300M to convert Riverdale paper machine »

International Paper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDTI

Integrated Device

$27.00

-0.16 (-0.59%)

09:26
09/22/17
09/22
09:26
09/22/17
09:26
Recommendations
Integrated Device analyst commentary  »

Integrated Device chip…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 05

    Oct

09:25
09/22/17
09/22
09:25
09/22/17
09:25
Conference/Events
DA Davidson engineering analyst holds an analyst/industry conference call »

Engineering &…

RBS

RBS

09:24
09/22/17
09/22
09:24
09/22/17
09:24
Upgrade
RBS rating change  »

RBS upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COR

CoreSite Realty

09:23
09/22/17
09/22
09:23
09/22/17
09:23
Initiation
CoreSite Realty initiated  »

CoreSite Realty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

CONE

CyrusOne

$60.41

-0.35 (-0.58%)

09:22
09/22/17
09/22
09:22
09/22/17
09:22
Initiation
CyrusOne initiated  »

CyrusOne initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

, S

Sprint

09:21
09/22/17
09/22
09:21
09/22/17
09:21
Hot Stocks
On The Fly: Pre-market Movers »

HIGHER: T-Mobile US…

TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

S

Sprint

EARS

Auris Medical

$0.71

0.0101 (1.44%)

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

FINL

Finish Line

$9.22

-0.21 (-2.23%)

FL

Foot Locker

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 27

    Sep

  • 02

    Oct

  • 16

    May

BWA

BorgWarner

, SEV

Sevcon

$22.00

-0.01 (-0.05%)

09:21
09/22/17
09/22
09:21
09/22/17
09:21
Conference/Events
Sevcon to host special shareholder meeting »

Special Shareholder…

BWA

BorgWarner

SEV

Sevcon

$22.00

-0.01 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

ICPT

Intercept

$73.70

-24.42 (-24.89%)

09:19
09/22/17
09/22
09:19
09/22/17
09:19
Downgrade
Intercept rating change  »

Intercept downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLR

Digital Realty

09:18
09/22/17
09/22
09:18
09/22/17
09:18
Initiation
Digital Realty initiated  »

Digital Realty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
09/22/17
09/22
09:18
09/22/17
09:18
Options
Overnight activity included 125 trades in SPX and 21 trades in VIX »

125 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAG

Conagra Brands

09:17
09/22/17
09/22
09:17
09/22/17
09:17
Hot Stocks
Conagra Brands to acquire Angie's Artisan Treats, terms not disclosed »

Conagra Brands announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 28

    Sep

09:15
09/22/17
09/22
09:15
09/22/17
09:15
General news
Euro$ interest rate futures have continued to steady »

Euro$ interest rate…

09:15
09/22/17
09/22
09:15
09/22/17
09:15
General news
Breaking General news story  »

Kansas City Federal…

HDSN

Hudson Technologies

$8.47

-0.79 (-8.53%)

09:14
09/22/17
09/22
09:14
09/22/17
09:14
Recommendations
Hudson Technologies analyst commentary  »

Roth says Hudson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

ACN

Accenture

09:11
09/22/17
09/22
09:11
09/22/17
09:11
Recommendations
Accenture analyst commentary  »

Accenture risk/reward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

  • 02

    Oct

  • 22

    Oct

FINL

Finish Line

$9.22

-0.21 (-2.23%)

09:10
09/22/17
09/22
09:10
09/22/17
09:10
Hot Stocks
Breaking Hot Stocks news story on Finish Line »

Finish Line still sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

DKS

Dick's Sporting

$26.23

-0.31 (-1.17%)

09:05
09/22/17
09/22
09:05
09/22/17
09:05
Hot Stocks
Dick's Sporting to open four new stores in three states in September »

DICK'S Sporting Good…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KTCC

Key Tronic

$6.84

-0.023 (-0.34%)

, CETX

Cemtrex

$3.21

-0.09 (-2.73%)

09:04
09/22/17
09/22
09:04
09/22/17
09:04
Hot Stocks
Bharat Parikh & Associates responds to Key Tronic's allegations »

Bharat Parikh &…

KTCC

Key Tronic

$6.84

-0.023 (-0.34%)

CETX

Cemtrex

$3.21

-0.09 (-2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.